Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study
Purpose Portal vein tumor thrombosis is a critical complication in patients with hepatocellular carcinoma (HCC). This prospective multicenter trial assessed the efficacy of hepatic arterial infusion chemoembolization therapy with cisplatin suspended in lipiodol combined with 5-fluorouracil for HCC p...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2016-02, Vol.77 (2), p.243-250 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | 2 |
| container_start_page | 243 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 77 |
| creator | Nagamatsu, Hiroaki Sumie, Shuji Niizeki, Takashi Tajiri, Nobuyoshi Iwamoto, Hideki Aino, Hajime Nakano, Masahito Shimose, Shigeo Satani, Manabu Okamura, Shusuke Kuromatsu, Ryoko Matsugaki, Satoshi Kurogi, Junichi Kajiwara, Masahiko Koga, Hironori Torimura, Takuji |
| description | Purpose
Portal vein tumor thrombosis is a critical complication in patients with hepatocellular carcinoma (HCC). This prospective multicenter trial assessed the efficacy of hepatic arterial infusion chemoembolization therapy with cisplatin suspended in lipiodol combined with 5-fluorouracil for HCC patients with portal vein tumor thrombosis.
Methods
We enrolled 52 HCC patients with portal vein tumor thrombosis. They received hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol and 5-fluorouracil. The primary efficacy endpoint was progression-free survival (PFS), while the secondary endpoints were overall survival (OS), tumor response rate, safety, and tolerability. Independent factors for survival were also evaluated.
Results
The median PFS and OS were 8.6 and 27.0 months, respectively. Ten patients showed complete response, while 29 had partial response (response rate, 75.0 %). The median survival time of 10 patients with complete response and 29 with partial response was 32 months, while that of 15 patients with partial response who later showed disappearance of HCC following additional therapies was 50 months. Multivariate analysis identified response to treatment and disappearance of viable HCC as independent predictors of survival. The treatment was well tolerated, and the only encountered Grade 3 toxicities were thrombocytopenia and hyperbilirubinemia.
Conclusions
Hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol combined with 5-fluorouracil is effective treatment for unresectable HCC with portal vein tumor thrombosis. |
| doi_str_mv | 10.1007/s00280-015-2892-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1764010455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3947241441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-2069d0c004d232ab9221182c33cd8d34b6cbd8dd48c9eb5f65df7fcef18c20ea3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMo7vrxA7xIwHN18tE2603EjwXBi55DmkzdLm1Tk1ZYf71ZVsWLpwyZZ54ZXkLOGFwygPIqAnAFGbA842rBs3KPzJkUPAMlxT6Zg5Ayy0uQM3IU4xoAJBPikMx4UeayKNWcTI84mLGx1IQRQ2Na2vT1FBvfU7vCzmNX-bb5TEj6GVcYzLChtQ_UuA_TW3R0tRV4i207tSZQa4Jtet-Za9pNbTJjn8R0WJmIdLmkcZzc5oQc1KaNePr9HpPX-7uX28fs6flheXvzlNkc1JhxKBYObDrbccFNteCcMcWtENYpJ2RV2CoVTiq7wCqvi9zVZW2xZspyQCOOycXOOwT_PmEc9dpPoU8rNSsLCQxknieK7SgbfIwBaz2EpjNhoxnobdB6F7ROQett0LpMM-ff5qnq0P1O_CSbAL4DYmr1bxj-rP7X-gVy3IuB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1764010455</pqid></control><display><type>article</type><title>Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nagamatsu, Hiroaki ; Sumie, Shuji ; Niizeki, Takashi ; Tajiri, Nobuyoshi ; Iwamoto, Hideki ; Aino, Hajime ; Nakano, Masahito ; Shimose, Shigeo ; Satani, Manabu ; Okamura, Shusuke ; Kuromatsu, Ryoko ; Matsugaki, Satoshi ; Kurogi, Junichi ; Kajiwara, Masahiko ; Koga, Hironori ; Torimura, Takuji</creator><creatorcontrib>Nagamatsu, Hiroaki ; Sumie, Shuji ; Niizeki, Takashi ; Tajiri, Nobuyoshi ; Iwamoto, Hideki ; Aino, Hajime ; Nakano, Masahito ; Shimose, Shigeo ; Satani, Manabu ; Okamura, Shusuke ; Kuromatsu, Ryoko ; Matsugaki, Satoshi ; Kurogi, Junichi ; Kajiwara, Masahiko ; Koga, Hironori ; Torimura, Takuji</creatorcontrib><description>Purpose
Portal vein tumor thrombosis is a critical complication in patients with hepatocellular carcinoma (HCC). This prospective multicenter trial assessed the efficacy of hepatic arterial infusion chemoembolization therapy with cisplatin suspended in lipiodol combined with 5-fluorouracil for HCC patients with portal vein tumor thrombosis.
Methods
We enrolled 52 HCC patients with portal vein tumor thrombosis. They received hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol and 5-fluorouracil. The primary efficacy endpoint was progression-free survival (PFS), while the secondary endpoints were overall survival (OS), tumor response rate, safety, and tolerability. Independent factors for survival were also evaluated.
Results
The median PFS and OS were 8.6 and 27.0 months, respectively. Ten patients showed complete response, while 29 had partial response (response rate, 75.0 %). The median survival time of 10 patients with complete response and 29 with partial response was 32 months, while that of 15 patients with partial response who later showed disappearance of HCC following additional therapies was 50 months. Multivariate analysis identified response to treatment and disappearance of viable HCC as independent predictors of survival. The treatment was well tolerated, and the only encountered Grade 3 toxicities were thrombocytopenia and hyperbilirubinemia.
Conclusions
Hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol combined with 5-fluorouracil is effective treatment for unresectable HCC with portal vein tumor thrombosis.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-015-2892-7</identifier><identifier>PMID: 26754678</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Cancer Research ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - physiopathology ; Carcinoma, Hepatocellular - therapy ; Chemoembolization, Therapeutic - methods ; Cisplatin - administration & dosage ; Disease-Free Survival ; Ethiodized Oil - administration & dosage ; Female ; Fluorouracil - administration & dosage ; Humans ; Infusions, Intra-Arterial - methods ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - physiopathology ; Liver Neoplasms - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Oncology ; Original Article ; Pharmacology/Toxicology ; Portal Vein - pathology ; Treatment Outcome ; Venous Thrombosis - diagnosis ; Venous Thrombosis - etiology ; Venous Thrombosis - therapy</subject><ispartof>Cancer chemotherapy and pharmacology, 2016-02, Vol.77 (2), p.243-250</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-2069d0c004d232ab9221182c33cd8d34b6cbd8dd48c9eb5f65df7fcef18c20ea3</citedby><cites>FETCH-LOGICAL-c508t-2069d0c004d232ab9221182c33cd8d34b6cbd8dd48c9eb5f65df7fcef18c20ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-015-2892-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-015-2892-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26754678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagamatsu, Hiroaki</creatorcontrib><creatorcontrib>Sumie, Shuji</creatorcontrib><creatorcontrib>Niizeki, Takashi</creatorcontrib><creatorcontrib>Tajiri, Nobuyoshi</creatorcontrib><creatorcontrib>Iwamoto, Hideki</creatorcontrib><creatorcontrib>Aino, Hajime</creatorcontrib><creatorcontrib>Nakano, Masahito</creatorcontrib><creatorcontrib>Shimose, Shigeo</creatorcontrib><creatorcontrib>Satani, Manabu</creatorcontrib><creatorcontrib>Okamura, Shusuke</creatorcontrib><creatorcontrib>Kuromatsu, Ryoko</creatorcontrib><creatorcontrib>Matsugaki, Satoshi</creatorcontrib><creatorcontrib>Kurogi, Junichi</creatorcontrib><creatorcontrib>Kajiwara, Masahiko</creatorcontrib><creatorcontrib>Koga, Hironori</creatorcontrib><creatorcontrib>Torimura, Takuji</creatorcontrib><title>Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
Portal vein tumor thrombosis is a critical complication in patients with hepatocellular carcinoma (HCC). This prospective multicenter trial assessed the efficacy of hepatic arterial infusion chemoembolization therapy with cisplatin suspended in lipiodol combined with 5-fluorouracil for HCC patients with portal vein tumor thrombosis.
Methods
We enrolled 52 HCC patients with portal vein tumor thrombosis. They received hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol and 5-fluorouracil. The primary efficacy endpoint was progression-free survival (PFS), while the secondary endpoints were overall survival (OS), tumor response rate, safety, and tolerability. Independent factors for survival were also evaluated.
Results
The median PFS and OS were 8.6 and 27.0 months, respectively. Ten patients showed complete response, while 29 had partial response (response rate, 75.0 %). The median survival time of 10 patients with complete response and 29 with partial response was 32 months, while that of 15 patients with partial response who later showed disappearance of HCC following additional therapies was 50 months. Multivariate analysis identified response to treatment and disappearance of viable HCC as independent predictors of survival. The treatment was well tolerated, and the only encountered Grade 3 toxicities were thrombocytopenia and hyperbilirubinemia.
Conclusions
Hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol combined with 5-fluorouracil is effective treatment for unresectable HCC with portal vein tumor thrombosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - physiopathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Cisplatin - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Ethiodized Oil - administration & dosage</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Infusions, Intra-Arterial - methods</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - physiopathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology/Toxicology</subject><subject>Portal Vein - pathology</subject><subject>Treatment Outcome</subject><subject>Venous Thrombosis - diagnosis</subject><subject>Venous Thrombosis - etiology</subject><subject>Venous Thrombosis - therapy</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1LxDAQhoMo7vrxA7xIwHN18tE2603EjwXBi55DmkzdLm1Tk1ZYf71ZVsWLpwyZZ54ZXkLOGFwygPIqAnAFGbA842rBs3KPzJkUPAMlxT6Zg5Ayy0uQM3IU4xoAJBPikMx4UeayKNWcTI84mLGx1IQRQ2Na2vT1FBvfU7vCzmNX-bb5TEj6GVcYzLChtQ_UuA_TW3R0tRV4i207tSZQa4Jtet-Za9pNbTJjn8R0WJmIdLmkcZzc5oQc1KaNePr9HpPX-7uX28fs6flheXvzlNkc1JhxKBYObDrbccFNteCcMcWtENYpJ2RV2CoVTiq7wCqvi9zVZW2xZspyQCOOycXOOwT_PmEc9dpPoU8rNSsLCQxknieK7SgbfIwBaz2EpjNhoxnobdB6F7ROQett0LpMM-ff5qnq0P1O_CSbAL4DYmr1bxj-rP7X-gVy3IuB</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Nagamatsu, Hiroaki</creator><creator>Sumie, Shuji</creator><creator>Niizeki, Takashi</creator><creator>Tajiri, Nobuyoshi</creator><creator>Iwamoto, Hideki</creator><creator>Aino, Hajime</creator><creator>Nakano, Masahito</creator><creator>Shimose, Shigeo</creator><creator>Satani, Manabu</creator><creator>Okamura, Shusuke</creator><creator>Kuromatsu, Ryoko</creator><creator>Matsugaki, Satoshi</creator><creator>Kurogi, Junichi</creator><creator>Kajiwara, Masahiko</creator><creator>Koga, Hironori</creator><creator>Torimura, Takuji</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160201</creationdate><title>Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study</title><author>Nagamatsu, Hiroaki ; Sumie, Shuji ; Niizeki, Takashi ; Tajiri, Nobuyoshi ; Iwamoto, Hideki ; Aino, Hajime ; Nakano, Masahito ; Shimose, Shigeo ; Satani, Manabu ; Okamura, Shusuke ; Kuromatsu, Ryoko ; Matsugaki, Satoshi ; Kurogi, Junichi ; Kajiwara, Masahiko ; Koga, Hironori ; Torimura, Takuji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-2069d0c004d232ab9221182c33cd8d34b6cbd8dd48c9eb5f65df7fcef18c20ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - physiopathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Cisplatin - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Ethiodized Oil - administration & dosage</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Infusions, Intra-Arterial - methods</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - physiopathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology/Toxicology</topic><topic>Portal Vein - pathology</topic><topic>Treatment Outcome</topic><topic>Venous Thrombosis - diagnosis</topic><topic>Venous Thrombosis - etiology</topic><topic>Venous Thrombosis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagamatsu, Hiroaki</creatorcontrib><creatorcontrib>Sumie, Shuji</creatorcontrib><creatorcontrib>Niizeki, Takashi</creatorcontrib><creatorcontrib>Tajiri, Nobuyoshi</creatorcontrib><creatorcontrib>Iwamoto, Hideki</creatorcontrib><creatorcontrib>Aino, Hajime</creatorcontrib><creatorcontrib>Nakano, Masahito</creatorcontrib><creatorcontrib>Shimose, Shigeo</creatorcontrib><creatorcontrib>Satani, Manabu</creatorcontrib><creatorcontrib>Okamura, Shusuke</creatorcontrib><creatorcontrib>Kuromatsu, Ryoko</creatorcontrib><creatorcontrib>Matsugaki, Satoshi</creatorcontrib><creatorcontrib>Kurogi, Junichi</creatorcontrib><creatorcontrib>Kajiwara, Masahiko</creatorcontrib><creatorcontrib>Koga, Hironori</creatorcontrib><creatorcontrib>Torimura, Takuji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagamatsu, Hiroaki</au><au>Sumie, Shuji</au><au>Niizeki, Takashi</au><au>Tajiri, Nobuyoshi</au><au>Iwamoto, Hideki</au><au>Aino, Hajime</au><au>Nakano, Masahito</au><au>Shimose, Shigeo</au><au>Satani, Manabu</au><au>Okamura, Shusuke</au><au>Kuromatsu, Ryoko</au><au>Matsugaki, Satoshi</au><au>Kurogi, Junichi</au><au>Kajiwara, Masahiko</au><au>Koga, Hironori</au><au>Torimura, Takuji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>77</volume><issue>2</issue><spage>243</spage><epage>250</epage><pages>243-250</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Purpose
Portal vein tumor thrombosis is a critical complication in patients with hepatocellular carcinoma (HCC). This prospective multicenter trial assessed the efficacy of hepatic arterial infusion chemoembolization therapy with cisplatin suspended in lipiodol combined with 5-fluorouracil for HCC patients with portal vein tumor thrombosis.
Methods
We enrolled 52 HCC patients with portal vein tumor thrombosis. They received hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol and 5-fluorouracil. The primary efficacy endpoint was progression-free survival (PFS), while the secondary endpoints were overall survival (OS), tumor response rate, safety, and tolerability. Independent factors for survival were also evaluated.
Results
The median PFS and OS were 8.6 and 27.0 months, respectively. Ten patients showed complete response, while 29 had partial response (response rate, 75.0 %). The median survival time of 10 patients with complete response and 29 with partial response was 32 months, while that of 15 patients with partial response who later showed disappearance of HCC following additional therapies was 50 months. Multivariate analysis identified response to treatment and disappearance of viable HCC as independent predictors of survival. The treatment was well tolerated, and the only encountered Grade 3 toxicities were thrombocytopenia and hyperbilirubinemia.
Conclusions
Hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol combined with 5-fluorouracil is effective treatment for unresectable HCC with portal vein tumor thrombosis.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>26754678</pmid><doi>10.1007/s00280-015-2892-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2016-02, Vol.77 (2), p.243-250 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_1764010455 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Agents - administration & dosage Cancer Research Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - physiopathology Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic - methods Cisplatin - administration & dosage Disease-Free Survival Ethiodized Oil - administration & dosage Female Fluorouracil - administration & dosage Humans Infusions, Intra-Arterial - methods Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - physiopathology Liver Neoplasms - therapy Male Medicine Medicine & Public Health Middle Aged Neoplasm Invasiveness Neoplasm Staging Oncology Original Article Pharmacology/Toxicology Portal Vein - pathology Treatment Outcome Venous Thrombosis - diagnosis Venous Thrombosis - etiology Venous Thrombosis - therapy |
| title | Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A49%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatic%20arterial%20infusion%20chemoembolization%20therapy%20for%20advanced%20hepatocellular%20carcinoma:%20multicenter%20phase%20II%20study&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Nagamatsu,%20Hiroaki&rft.date=2016-02-01&rft.volume=77&rft.issue=2&rft.spage=243&rft.epage=250&rft.pages=243-250&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-015-2892-7&rft_dat=%3Cproquest_cross%3E3947241441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1764010455&rft_id=info:pmid/26754678&rfr_iscdi=true |